Vertebral Technologies Inc. has Over 2,000 Devices Implanted
MINNETONKA, Minn., May 2, 2012 /PRNewswire-iReach/ — Vertebral Technologies, Inc. (VTI), a spinal implant developer and manufacturer, announced today that over 2,000 InterFuse® interbody fusion devices have been implanted, including the 100th implant of the InterFuse T™, the TLIF fusion device.
“Vertebral Technologies is pleased with the continued growth and development of the InterFuse System. There have now been over 2,000 devices implanted in the U.S., with 100 using the new InterFuse T™ device, which utilizes the TLIF approach,” saidJeffrey Felt M.D., Chairman and CEO of VTI. “I am proud of the superior product that our engineering team has designed and developed.” The InterFuse T™ device allows surgeons to use the familiar and popular TLIF approach while achieving a larger footprint than current devices allow. This is accomplished by building a cage inside the disc space with three interlocking PEEK modular segments. The implant may be placed by a minimally invasive technique through a tube or via a mini-open technique. In addition to the TLIF product, the company also offers the InterFuse S™ device, which is implanted from a posterior approach. Furthermore, VTI also offers the InterFuse DA™, a modular ALIF device.
Additionally, March 2012 marked the month with the highest number of implantations in VTI’s history. This landmark month showcased that the InterFuse line is growing and expanding its distribution territory. With recent instrument design changes, the insertion technique has become even smoother. The updated technique has received positive feedback from surgeons in the field and at VTI hosted skills labs. With a positive Q1 under its belt, VTI anticipates further growth and success in the months to come.
About Vertebral Technologies, Inc.
Vertebral Technologies, Inc. is a privately held company developing and commercializing improved and less-invasive spinal therapies. The company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the InterFuse®, an interbody fusion device, in June 2008. The fusion device is sold through a national distribution network. The InterCushion, a new motion preserving device, is currently not available for sale and does not have FDA clearance in the United States. For additional information contact Tom Boyd at 952.912.5400 or visit www.vti-spine.com.
Media Contact: Tom Boyd Vertebral Technologies, Inc., 952.912.5400, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Vertebral Technologies, Inc.